This inventor holds 1 USPTO granted patent. Top assignee: University System of Maryland. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations by Daniel Grun in Cancer Treatment
Introduction
Daniel Grun is an accomplished inventor based in Derwood, MD (US). He has made significant contributions to the field of cancer treatment, particularly in addressing drug-resistant cancers. His innovative approaches have the potential to improve patient outcomes and advance cancer therapy.
Latest Patents
Daniel Grun holds a patent for "Methods of treating resistant cancers." This patent outlines a method for reducing resistance in individuals with drug-resistant cancers, such as those resistant to BRAF inhibitors. The method involves administering a Hippo signaling pathway inhibitor, which may include a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, or a Transcription enhancer domain (TEAD) inhibitor. Additionally, the patent describes a method for treating BRAF inhibitor resistance in individuals with malignant melanoma using a combination of a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor. Daniel Grun has 1 patent to his name.
Career Highlights
Daniel Grun is affiliated with the University System of Maryland, where he continues to engage in research and development in the field of cancer treatment. His work focuses on innovative methods to combat drug resistance in cancer therapies, which is a critical challenge in oncology.
Collaborations
Daniel collaborates with notable colleagues, including Wen Xu and Gautam Adhikary. Their combined expertise contributes to the advancement of research in cancer treatment and the development of new therapeutic strategies.
Conclusion
Daniel Grun's innovative work in treating resistant cancers showcases his commitment to improving cancer therapies. His contributions have the potential to make a significant impact in the field of oncology and enhance the lives of patients facing drug-resistant cancers.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
